期刊文献+

HIV暴露婴儿预防接种免疫效果报告 被引量:1

Report on Vaccine- induced Immunity of HIV- exposed Infants
下载PDF
导出
摘要 目的为评估经HIV母婴阻断措施后该类婴儿群对卡介苗、乙肝疫苗的免疫反应能力,为相关部门制定此类婴儿的预防接种政策提供依据。方法为HIV感染孕妇提供综合性母婴阻断措施,将其婴儿设为观察组,母亲HIV阴性婴儿为对照组。对2组婴儿按常规进行预防接种,在接种卡介苗3~6个月后作结核菌素(PPD)试验、乙肝疫苗7~10个月后作乙肝抗体(抗-HBs)水平检测。结果 HIV感染孕妇经孕期规范抗病毒治疗后母婴阻断效果明显,其婴儿感染率远低于未治疗者。2组婴儿的PPD阳性率及卡痕阳性率均达90%以上;抗-HBs水平,观察组为296.83±3.10mIU/mL,对照组为354.30±2.37mIU/mL。结论本组资料显示,HIV阳性孕妇经综合性HIV母婴阻断措施后其所娩婴儿对乙肝疫苗和卡介苗具有类似于普通婴儿的免疫反应能力。 The purpose is to investigate immune tolerance and the efficacy of hepatitis B vaccine and BCG immunization of infants on the prevention of mother to child transmission(PMTCT) programs, in order to provide the basis for corresponding vaccination policy. We provide PMTCT service to HIV-positive mothers and define infants of HIV-positive mothers as experimental group(EG), while infants beard by HIV-negative mothers as comparative group (CG). The two groups were vaccinated regularly and had PPD tests and anti-HBs level tests. In consequence, the HIV prevalence in infants born to mothers on the PMTCT programs is substantially lower than infants not in the program.The PPD-positive rates of the both groups are above 90%, and the mean content of anti-HBs for EG and CG are 296.83±3.10mIU/mL and 354.30±2.37mIU/mL respectively. In conclusion, the efficacy of hepatitis B and BCG vaccine immunization of infants born to HIV-positive mothers is similar to normal infants.
出处 《中国药物警戒》 2010年第10期588-591,共4页 Chinese Journal of Pharmacovigilance
基金 2008年度广西医疗卫生计划课题 立项文件:广西卫生厅桂卫科教200825号 合同号:Z2008344
关键词 HIV暴露婴儿 预防接种 免疫效果 HIV-exposed infants vaccination immunity effect
  • 相关文献

参考文献3

二级参考文献44

  • 12006年我国艾滋病防治工作稳步推进[J].中国艾滋病性病,2007,13(2):99-100. 被引量:26
  • 2[1]WHO.BCG vaccine(WHO position paper)[J].WER,2004,79(4):27-38.
  • 3[2]WHO.Core information for the development of immunization policy[R],Geneva:WHO/V & B.2002.
  • 4[3]WHO.Immunization in practice:a practical resource guide for Health workers[M].Geneva:WHO/IVB.2004.
  • 5[4]WHO.Measles vaccines(WHO position paper)[J].WER,2004,79(14):130-142.
  • 6[5]WHO.Vaccine introduction guidelines.Adding a vaccine to a national immunization programme:decision and implementation[R].Geneva:WHO/IVB.2005.
  • 7[6]WHO.Yellow fever vaccine(WHO position paper)[J].WER,2003,78(40):349-359.
  • 8[7]WHO.Typhoid vaccines(WHO position paper)[J].WER,2000,75(32):257-264.
  • 9[8]WHO.Pertussis vaccines(WHO position paper)[J].WER,2005.80(4):31-39.
  • 10[9]WHO.Influenza vacdnes(WHO position paper)[J].WER,2005,80(33)1279-287.

共引文献866

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部